GlassScriptPhysician profile
Sima Kavand
NPI 1316380934
$1,486.62
in general payments reported to CMS, 2019-2025
24 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $135 · 2023: $347 · 2024: $547 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.13 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $221.87 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Novo Nordisk INC | $189.75 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ucb, INC. | $134.53 | 2022 | |
| Lilly USA, LLC | $120.47 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Corcept Therapeutics | $113.06 | 2024-2025 | Korlym |
| Dexcom, INC. | $85.40 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $83.45 | 2023-2025 | Gvoke Hypopen |
| Abbvie INC. | $67.90 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.35 | 2025 | |
| Exact Sciences Corporation | $63.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $44.68 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $38.92 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.65 | 2023 | Xifaxan, Cycloset |
| Glaxosmithkline, LLC. | $32.56 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Seqirus USA INC | $26.28 | 2025 | Fluad, Flucelvax |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $23.42 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $22.99 | 2023 | |
| Mannkind Corporation | $21.53 | 2024 | |
| Insulet Corporation | $19.01 | 2024 | Omnipod |
| Medtronic, INC. | $17.24 | 2025 | Venaseal |
| Ibsa Pharma INC. | $15.74 | 2025 | Tirosint, Licart, Flector |
| Acella Pharmaceuticals, LLC | $15.06 | 2023 | NP Thyroid 60 |
| Amneal Pharmaceuticals LLC | $14.96 | 2024 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $14.56 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Kavand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.